Mallinckrodt, Endo announce leadership for merged company

Mallinckrodt and Endo announced the future executive team that will drive the creation of global, scaled, diversified therapeutics company in both the branded specialty pharmaceuticals and the generics and sterile injectables (GxSI) businesses.

As announced on March 13, 2025, the proposed merger of Mallinckrodt and Endo envisions creating both a branded specialty pharmaceuticals company and, later, separating the generic pharmaceuticals businesses of the two companies along with Endo’s sterile injectable operations, which is currently intended to be implemented through a spin-off of the separated businesses in an independent entity. The merger remains on course to be completed in the second half of this year, subject to approval by shareholders of both companies and customary closing conditions.

The announcement details the leadership team that will be assembled from Mallinckrodt and Endo, as well as critical executive functions for which new leaders will be recruited to help lead these businesses into a new era of growth and change.

[Related: Mallinckrodt and Endo to merge]

“As we combine two companies with a rich legacy of innovation, we are building a highly capable and balanced team of proven leaders to help create a promising new future,” said Siggi Olafsson, president and CEO of Mallinckrodt, who will become president and CEO of the combined company. 

Olafsson added, “The leadership team of our newly combined company, along with the leaders of the GxSI business, will include executives from both Mallinckrodt and Endo who have deep experience and institutional knowledge, as well as new talent that will provide fresh insight and perspective. We are excited to bring together two great companies for the ultimate benefit of the patients we serve, and we thank employees of both companies for their tremendous work and efforts toward closing this merger.”

The following executives will form the core of the senior leadership team of the merged company:

• Tracy Basso, chief human resources officer, Endo;
• Mark Bradley, chief financial officer, Endo, will serve as chief integration officer;
• Lisa French, chief commercial officer, Mallinckrodt;
• Henriette Nielsen, chief transformation officer, Mallinckrodt;
• Paul O’Neill, quality and operations, specialty brands, Mallinckrodt;
• Cheryl Stouch, chief information officer, Endo;
• Mark Tyndall, chief legal officer & corporate secretary, Mallinckrodt; and,
• Susan Williamson, chief compliance officer, Endo.